Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
The grant seeks to enhance cancer research by using advanced molecular imaging to gain insights into inflammation dynamics in vivo.
Funder: National Institutes of Health
Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | Additional cycles through November 2027
Funding Amounts: Up to $500,000 direct costs/year, max 5 years; budgets must reflect actual project needs
Summary: Supports interdisciplinary R01 research to develop and apply molecular imaging methods for in vivo investigation of cancer inflammation dynamics.
Key Information: Multiple PIs required (cancer biology & imaging); single-PI applications are not allowed and will be withdrawn.
Description
This opportunity, offered by the National Cancer Institute (NCI) at NIH, funds R01 research projects that develop and use advanced molecular imaging technologies to gain fundamental, mechanistic insights into inflammation in cancer—specifically in vivo. The initiative addresses the current gap where most research relies on in vitro or ex vivo methods, limiting understanding of the dynamic interactions between cancer and inflammation.
The program strongly encourages interdisciplinary, team-based science, requiring at least two Principal Investigators: one with expertise in cancer biology (including cancer physiology, immunology, or inflammation) and one in imaging science. Projects must integrate both fields to advance knowledge of how inflammation influences cancer development, progression, and response to therapy.
Key research areas include, but are not limited to:
- Development of targeted imaging probes and reporter genes for cancer inflammation biomarkers and immune cells.
- High-resolution, quantitative, and multimodal imaging to monitor molecular and cellular changes in cancer inflammation.
- Integration of in vivo imaging with multi-omics or spatial imaging to address mechanistic hypotheses.
- Application of imaging tools to study immune cell migration, immunosuppression, tumor microenvironment, and therapy monitoring.
Applications that do not include both cancer biology and imaging expertise, or that focus solely on in vitro/ex vivo methods, will be considered non-responsive.
